Phase II study of S-1 plus Bevacizumab combination chemotherapy for patients with non-small-cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2017 Status changed from recruiting to discontinued.
- 03 Jan 2011 New trial record